Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

324

Participants

Timeline

Start Date

October 21, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

Busulfan

Given IV

DRUG

Cladribine

Given IV

DRUG

Fludarabine Phosphate

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo stem cell transplantation

DRUG

Thiotepa

Given IV

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER